ホーム › 急性骨髄性白血病 › コネチカット州 › New Haven
New Haven、CTにおける急性骨髄性白血病の臨床試験
New Havenとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する17件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3マイル先
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
被験者募集中第1相
- Yale University, New Haven
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Yale University, New Haven
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Yale University, New Haven
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven · 3マイル先
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
被験者募集中第3相
- Yale University, New Haven
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- Yale University, New Haven
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- Yale University, New Haven
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
被験者募集中第3相
- Yale University School of Medicine, New Haven
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
被験者募集中第1相
- Smilow Cancer Hospital at Yale New Haven, New Haven
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
被験者募集中第1相
- Yale University, Yale Cancer Center, New Haven
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- Yale New Haven Hospital, New Haven
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
被験者募集中第1相
- Yale New Haven Hospital, New Haven
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
被験者募集中第2/3相
- Yale University, New Haven
Revumenib in Combination With 7+3 + Midostaurin in AML
被験者募集中第1相
- Yale Cancer Center, New Haven
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
被験者募集中第1相
- Yale Cancer Center and Smilow Cancer Hospital, New Haven
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
被験者募集中第1/2相
- Yale University, New Haven
他の都市における急性骨髄性白血病の試験
- Houston, TX85件の研究
- New York City, NY51件の研究
- Boston, MA44件の研究
- Seattle, WA41件の研究
- Baldwin Park, CA40件の研究
- Columbus, OH35件の研究
- Philadelphia, PA34件の研究
- Durham, NC33件の研究
- Atlanta, GA31件の研究
- Tampa, FL29件の研究
- Chicago, IL26件の研究
- Portland, OR25件の研究
New Havenにおける他の研究
- 非小細胞肺癌41件の研究
- 乳がん38件の研究
- がん（全種類）33件の研究
- 転移性癌23件の研究
- 肺がん22件の研究
- 頭頸部扁平上皮癌22件の研究
- 卵巣がん21件の研究
- 大腸癌20件の研究
- 前立腺がん20件の研究
- アルコール使用障害（AUD）17件の研究
- オピオイド過剰摂取17件の研究
- 膵臓がん16件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。